New insights into the genetic basis of premature ovarian insufficiency: Novel causative variants and candidate genes revealed by genomic sequencing

Highlights

• Our study has provided new insights or strengthened recent claims about the etiology of premature ovarian insufficiency.

• Genomic sequencing reveals novel causative variants in STAG3, GDF9, FANCM, and FSHR, and new candidate genes, NRIP1, XPO1, and MACF1.

• We validate that GDF9 and FANCM are responsible for autosomal recessive premature ovarian insufficiency.

• Genetic heterogeneity of ovarian deficiency, incomplete understanding of its genetics, and singleton DNA sequencing are limiting factors.

Abstract

Ovarian deficiency, including premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR), represents one of the main causes of female infertility. POI is a genetically heterogeneous condition but current understanding of its genetic basis is far from complete, with the cause remaining unknown in the majority of patients. The genes that regulate DOR have been reported but the genetic basis of DOR has not been explored in depth. Both conditions are likely to lie along a continuum of degrees of decrease in ovarian reserve. We performed genomic analysis via whole exome sequencing (WES) followed by in silico analyses and functional experiments to investigate the genetic cause of ovarian deficiency in ten affected women. We achieved diagnoses for three of them, including the identification of novel variants in STAG3, GDF9, and FANCM. We identified potentially causative FSHR variants in another patient. This is the second report of biallelic GDF9 and FANCM variants, and, combined with functional support, validates these genes as bone fide autosomal recessive “POI genes”. We also identified new candidate genes, NRIP1, XPO1, and MACF1. These genes have been linked to ovarian function in mouse, pig, and zebrafish respectively, but never in humans. In the case of NRIP1, we provide functional support for the deleterious nature of the variant via SUMOylation and luciferase/β-galactosidase reporter assays. Our study provides multiple insights into the genetic basis of POI/DOR. We have further elucidated the involvement of GDF9, FANCM, STAG3 and FSHR in POI pathogenesis, and propose new candidate genes, NRIP1, XPO1, and MACF1, which should be the focus of future studies.

Introduction

Women are born with their future oocyte supply, which is established during development and reaches its maximum size of ∼5 million germ cells around 20 weeks of gestation. After this peak, there is a steady atresia of oocytes with ∼1−2 million by birth, further depleted to about half a million by menarche [1,2]. After menarche, women lose an average of 1000 oocytes per month, one of which completes maturation and is ovulated as part of the menstrual cycle [3]. The number of oocytes within each woman, corresponding to the ovarian reserve, is variable [4]. The cyclic oocyte maturation and loss of ovarian reserve occurs until menopause at an average age of 51 in the western world.

Ovarian deficiency, including premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR), is one of the main causes of female infertility. A DOR is mostly the consequence of age but is considered abnormal if it occurs before the age of 40 (10 % of women) [4]. In contrast, premature ovarian insufficiency (POI) is characterized by perturbation or cessation of the menstrual cycle along with elevated gonadotropins before the age of 40, affecting as many as 1 in 100 women. There is no evidence that DOR is a precursor of POI and women under 40 can have a DOR without POI. Nevertheless, these conditions are likely manifestations along a continuum of ovarian deficiency with different severity of decrease in ovarian reserve. POI can be devastating for affected women who face infertility, as well as an increased risk of co-morbidities such as cardiovascular disease, mental health problems, osteoporosis and earlier mortality [5,6]. The cause of POI is manifold. It can be secondary to medical interventions or can occur as part of autoimmune conditions, metabolic conditions or genetic syndromes. There is a tendency for affected individuals to have affected family members, indicating the role of inheritance in the condition [7,8]. The genetic basis of POI is further demonstrated by the discovery of causative variants in over 50 different genes [6]. These genes have diverse roles including metabolism, folliculogenesis, gonadogenesis, oogenesis, DNA damage repair, apoptosis, hormone signaling, autoimmunity and more. Current understanding of the genetic basis of POI, however, is far from complete, with the cause remaining unknown in the majority of patients, particularly those with sporadic and isolated POI. Key regulating genes of DOR have also been reported [9] but the genetic basis of DOR has not been explored in depth. Importantly, overlapping genetic background has been reported for POI and DOR [10] providing rationale for testing both conditions using similar methods.

In this study, we have used whole-exome sequencing (WES) followed by thorough variant curation and functional validation to investigate the genetic cause of POI and DOR in a small cohort of 10 patients. All patients had isolated POI or DOR with no related medical history, and were initially analysed as singletons. We were able to provide likely genetic diagnoses to three patients who harboured novel variants in the known POI-related genes STAG3, GDF9, and FANCM. Another patient had variants of uncertain significance with high clinical relevance in FSHR. We also propose the potential involvement of variants in NRIP1, XPO1, and MACF1, three genes known to have a role in ovarian biology but never before associated with human POI.